Prolight Diagnostics

0,255

SEK

-1,16 %

Mindre end 1K følgere

PRLD

Nordic SME

Medical Equipment & Services

Health Care

Overview

Ownership

Investor consensus

Sammenligne

-1,16%

-39,14%

-49%

+90,3%

+75,86%

+110,74%

-25%

-89,55%

-40,7%

Prolight Diagnostics develops test systems in POCT (Point of care testing). The tests are used outside of hospital laboratories to enable rapid assessments of the health of patients. The company's POCT platform is under development with the intention of measuring various biomarkers simultaneously. An important component of the work is to reduce the time for test results, particularly important for patients with heart problems. The company was founded in 1999 and is based in Lund.

Læs mere

Markedsværdi

179,03 mio. SEK

Aktieomsætning

424,73 t SEK

Omsætning

EBIT %

P/E

Udbytteafkast, %

Finanskalender

10.6

2025

Ekstraordinær generalforsamling '25

24.6

2025

Generalforsamling '25

28.8

2025

Delårsrapport Q2'25

Alle

Selskabsmeddelelser

Eksterne analyser

ViserAlle indholdstyper

Selskabsmeddelelsei går

Prolight Diagnostics publishes quarterly report Q1, 2025

Prolight Diagnostics

Pressemeddelelse28.5.2025, 09.55

Biostock publishes article about the positive pre-clinical results and coming milestone for Prolight Diagnostics in Q2

Prolight Diagnostics

Pressemeddelelse28.5.2025, 08.17

BioStock: Prolight’s CSO reflects on positive pre-clinical results and looks ahead to key milestone in Q2

Prolight Diagnostics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Create account

Selskabsmeddelelse26.5.2025, 16.15

NOTICE OF THE ANNUAL GENERAL MEETING IN PROLIGHT DIAGNOSTICS AB (PUBL)

Prolight Diagnostics

Eksterne analyser23.5.2025, 09.21

Prolight Diagnostics: Gearing up for commercialisation with strong insider backing - Emergers

Strong insider commitment signals confidence As expected, Prolight has now announced a rights issue of SEK 100m to finance the development of Psyros and reach commercialisation. The announcement contains several noteworthy points, of which a–c are particularly...

Prolight Diagnostics

Pressemeddelelse23.5.2025, 06.25

Emergers publishes updated analysis about Prolight Diagnostics

Prolight Diagnostics

Pressemeddelelse23.5.2025, 06.00

Emergers: Equity Research | Prolight Diagnostics AB: Gearing up for commercialisation with strong insider backing

Prolight Diagnostics

Selskabsmeddelelse21.5.2025, 16.45

NOTICE OF EXTRAORDINARY GENERAL MEETING IN PROLIGHT DIAGNOSTICS AB (PUBL)

Prolight Diagnostics

Selskabsmeddelelse21.5.2025, 16.25

Prolight has resolved on a rights issue of shares to complete the development of the Point of Care system Psyros™ and reach commercialisation

Prolight Diagnostics

Pressemeddelelse9.5.2025, 06.00

Prolight receives new MicroFlex patent approval in the US

Prolight Diagnostics

Pressemeddelelse28.4.2025, 06.00

Prolight secures first two European patents for Psyros™ technology

Prolight Diagnostics

Pressemeddelelse23.4.2025, 08.45

Study highlights speed of biomarker integration on Psyros POC platform

Prolight Diagnostics

Eksterne analyser1.4.2025, 07.38

Prolight: Positive results from the pre-clinical validation study de-risk the full clinical validation - Emergers

Following the many recent grants, notices of allowance and intention to grant patents in Europe and the US, and the arrival of the first of thirty commercial prototype instruments for the Psyros Point of Care (POC) system, Prolight has now announced ...

Prolight Diagnostics

Pressemeddelelse1.4.2025, 06.00

Emergers: Equity Research | PROLIGHT: Positive results from the pre-clinical validation study de-risk the full clinical validation

Prolight Diagnostics

Selskabsmeddelelse31.3.2025, 06.00

Prolight Diagnostics

0,255

SEK

-1,16 %

Finanskalender

Prolight Diagnostics publishes quarterly report Q1, 2025

Biostock publishes article about the positive pre-clinical results and coming milestone for Prolight Diagnostics in Q2

BioStock: Prolight’s CSO reflects on positive pre-clinical results and looks ahead to key milestone in Q2

Join Inderes community

Inderes account

NOTICE OF THE ANNUAL GENERAL MEETING IN PROLIGHT DIAGNOSTICS AB (PUBL)

Prolight Diagnostics: Gearing up for commercialisation with strong insider backing - Emergers

Emergers publishes updated analysis about Prolight Diagnostics

Emergers: Equity Research | Prolight Diagnostics AB: Gearing up for commercialisation with strong insider backing

NOTICE OF EXTRAORDINARY GENERAL MEETING IN PROLIGHT DIAGNOSTICS AB (PUBL)

Prolight has resolved on a rights issue of shares to complete the development of the Point of Care system Psyros™ and reach commercialisation

Prolight receives new MicroFlex patent approval in the US

Prolight secures first two European patents for Psyros™ technology

Study highlights speed of biomarker integration on Psyros POC platform

Prolight: Positive results from the pre-clinical validation study de-risk the full clinical validation - Emergers

Emergers: Equity Research | PROLIGHT: Positive results from the pre-clinical validation study de-risk the full clinical validation

Prolight announces positive pre-clinical data

Prolight receives notice of allowance for MicroFlex patent

The Psyros™ Cartridge Pilot Manufacturing line achieves another milestone!

Prolight Diagnostics publishes year-end report 2024

Prolight receives second Notice of Intention to Grant from European Patent Office for Psyros™ technology

Prolight receives Notice of Intention to Grant for core Psyros™ patent